Mustang Bio, Inc.
377 Plantation Street
Worcester
MA
01605
United States
Tel: 781-652-4500
Website: http://www.mustangbio.com/
Email: info@mustangbio.com
119 articles with Mustang Bio, Inc.
-
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
3/29/2023
Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO) today announced financial results and recent corporate highlights for the full year ended December 31, 2022.
-
Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium
3/28/2023
Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in Cantor’s The Future of Oncology Virtual Symposium.
-
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
1/17/2023
Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference.
-
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
12/19/2022
Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced recent CAR T cell therapy portfolio updates and provided anticipated milestones for 2023.
-
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
11/14/2022
Mustang Bio, Inc. announced financial results and recent corporate highlights for the third quarter ended September 30, 2022.
-
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
10/6/2022
Mustang Bio, Inc. today announced that the first patient has been treated in its multicenter, open-label, non-randomized Phase 1/2 clinical trial evaluating the safety and efficacy of MB-106, Mustang’s first-in-class CD20-targeted, autologous CAR T cell therapy for the treatment of relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHL”) and chronic lymphocytic leukemia (“CLL”).
-
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
9/8/2022
Mustang Bio, Inc. announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.
-
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8/11/2022
Mustang Bio, Inc. announced financial results and recent corporate highlights for the second quarter ended June 30, 2022.
-
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
7/27/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the first patient successfully received LV-RAG1 ex vivo lentiviral gene therapy to treat recombinase-activating gene-1 (“RAG1”) severe combined immunodeficiency.
-
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
6/22/2022
Mustang Bio, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to MB-106, Mustang’s CD20-targeted, autologous CAR T cell therapy for the treatment of Waldenstrom macroglobulinemia, a rare type of B-cell non-Hodgkin lymphoma.
-
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
6/13/2022
Mustang Bio, Inc. announced that updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, show a favorable safety profile, high overall response and complete response rates, and CAR T persistence in patients with follicular lymphoma.
-
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
5/19/2022
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107.
-
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
5/12/2022
Mustang Bio, Inc. announced financial results and recent corporate highlights for the first quarter ended March 31, 2022.
-
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
5/12/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that results from the follicular lymphoma (“FL”) cohort of the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”) were selected for an oral presentation at the European Hematology Association 2022 Hybrid Congress.
-
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting
5/3/2022
Mustang Bio, Inc. today announced that interim Phase 1/2 data on treatment with the same lentiviral vector used in MB-107.
-
A roundup of last week's top clinical trial updates and news.
-
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
4/25/2022
Mustang Bio, Inc. today announced updated interim data from the ongoing Phase 1/2 clinical trial of MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“B-NHLs”) and chronic lymphocytic leukemia (“CLL”).
-
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
4/21/2022
Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”).